' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Intraoperative Tumor Bed Boost With Electrons in Breast Cancer of Clinical Stages I Through III: Updated 10-Year Results.
Kaiser, J; Kronberger, C; Moder, A; Kopp, P; Wallner, M; Reitsamer, R; Fischer, T; Fussl, C; Zehentmayr, F; Sedlmayer, F; Fastner, G;
Int J Radiat Oncol Biol Phys. 2018; 102(1): 92-101.
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Fastner Gerd
Fischer Thorsten
Kronberger Cornelia
Reitsamer Roland
Sedlmayer Felix
Zehentmayr Franz

Abstract

PURPOSE
To assess retrospectively the role of an anticipated intraoperative tumor electron radiation therapy (IOERT) as a bed boost during breast-conserving surgery followed by conventional whole breast irradiation (WBI).
An unselected cohort of 770 breast cancer patients of all risk types was analyzed in terms of local control (LC) and survival outcome. Patients were treated by breast-conserving surgery, IOERT of 10 Gy, and WBI to total median doses of 54 Gy (range, 1.6-2). Patients were retrospectively analyzed for LC, locoregional control, metastasis-free survival (MFS), overall survival (OS), and breast cancer-specific survival (BCSS).
After a median follow-up of 121 months (range, 4-200), 21 (2.7%) in-breast recurrences (IBRs) were observed, 107 patients (14%) died and 106 (14%) developed metastases. Ten-year rates of LC, locoregional control, MFS, OS, and BCSS amounted to 97.2%, 96.5%, 86%, 85.7%, and 93.2 %, respectively. In multivariate analysis, HER2+ and triple-negative breast cancer subtype (TN) turned out to be significant negative predictors for IBRs (hazard ratios, 15.02 and 12.87, respectively; P < .05). Sorted by subtypes, 10-year LC rates were observed in 98.7% (range, 96.7%-99.5%) (luminal A), 98% (range, 94%-99.3%) (luminal B), 87.9% (range, 66.2%-96%) (HER2+), and 89% (range, 76.9%-94.9%) (TN), respectively.
After 10 years, boost IOERT maintains high LC rates in any risk setting.